Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN
Novartis Pharmaceuticals
Atherosclerotic cardiovascular disease (ASCVD)
1 trial -
ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN
Novartis Pharmaceuticals
Non-obstructive Coronary Artery Disease
1 trial -
Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)
The George Institute
Rabies infection/prophylaxis
1 trial -
Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)
The George Institute
Rabies
1 trial -
Ramelteon SL (Dose 1)
Takeda
Bipolar Disorder
1 trial -
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
Sanofi-aventis Healthcare Pty Ltd
multiple sclerosis
1 trial -
Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors
Sanofi-aventis Healthcare Pty Ltd
Non-small cell lung cancer metastatic
1 trial -
Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules
Gedeon Richter Plc.
Adolescent Patients (13 to 17 years of age) with Schizophrenia
1 trial -
Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection
Celgene Europe Limited
Myelodysplastic syndrome
1 trial -
Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection
Celgene Europe Limited
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 trial -
Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV InfectioN
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
Recombinant Factor VIII (BAY81-8973)
Bayer HealthCare AG
Blood Coagulation Disorders
1 trial -
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
BRIGHT MINDS BIOSCIENCES INC.
Human Papillomavirus Infection
1 trial -
Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
Livzon Pharmaceutical Group
COVID-19 Pandemic
1 trial -
Recommended treatment schedule
Prime Medicine
COVID-19
1 trial -
Relacorilant, 100 mg and 25 mg
CORCEPT THERAPEUTICS INC
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
Remdesivir
The First People's Hospital of Lianyungang
Covid19
1 trial -
Remternetug, Placebo to match LY
Eli Lilly Co.
Alzheimer’s Disease
1 trial -
Retatrutide, Tirzepatide, Retatrutide, Tirzepatide, Tirzepatide, Tirzepatide, Retatrutide, Retatrutide, Retatrutide, Tirzepatide, Tirzepatide
Eli Lilly Co.
Obesity
1 trial -
Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)
Incyte
Squamous Carcinoma of the Anal Canal
1 trial -
Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 25 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 10 mg powder and solvent for solution for injection for paediatric use, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempi
The George Institute
juvenile idiopathic arthritis
1 trial -
Revatio 0.8 mg/ml solution for injection
Pari Pharma GmbH
Hypoxic ischemic encephalopathy
1 trial -
Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa
Sanofi-aventis Healthcare Pty Ltd
Plasma cell myeloma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources